Huge Insider Buying at a Software Giant, Railroad Operator, and More
In the past week, insiders returned to scoop up more shares of a fracking services company and a recreational boat maker.
Headquartered in Stamford, CT Fiscal year ends December NASDAQ: WGS genedx.com
GeneDx Holdings Corp. is a genomics diagnostics company focused on rare disease diagnosis.
Its core products are its exome and genome sequencing tests, ExomeDx and GenomeDx. These are offered as standard, rapid and ultrarapid tests and in a prenatal version, and have been granted FDA Breakthrough Device designation. They are powered by GeneDx Infinity, a rare disease genomic dataset the company says spans more than 2.5 million genetic tests and about 1 million exomes and genomes.
The company earns most of its revenue from diagnostic tests reimbursed by commercial payers and Medicaid. Smaller revenue lines include:
- Legacy targeted panel tests.
- Data information services for biopharma, used for drug discovery, clinical trial enablement and real-world evidence.
- Software and interpretation services, including capabilities from its Fabric Genomics acquisition.
GeneDx's foundational customers are geneticists and pediatric specialists. It is expanding into NICUs, general pediatricians, prenatal care, adult specialists (starting with neurologists) and international markets. It is also developing genomic newborn screening (through the GUARDIAN and BRIDGES-NBS studies), new direct-access online channels, and biopharma sponsored testing programs. Updated
In the past week, insiders returned to scoop up more shares of a fracking services company and a recreational boat maker.
In the past week, insiders returned to scoop up more shares of a fracking services company and a recreational boat maker.
GeneDx Holdings Corp. is a genomics diagnostics company focused on rare disease diagnosis. Its core products are its exome and genome sequencing tests, ExomeDx and GenomeDx.
The Wall Street consensus 12-month price target for WGS is $82.00.